Posts by Sandra Ansanay-Alex
UNIGE 3R Prize 2025 Awarded for Breakthrough in Kidney Cancer Research
Since 2016, the University of Geneva (UNIGE) has awarded the 3R Prize to recognize research that advances the replacement, reduction, or refinement (3R) of animal use in science. The 2025 prize was awarded on 3 June 2025 to Prof. Patrycja Nowak-Sliwinska and Dr. Daniel Benamran for developing a novel protocol to culture kidney cancer organoids…
Read MoreClaire Charmet is the New CEO of CHUV
The new CEO of CHUV took up her position on 1 June 2025. Claire Charmet is already familiar with the institution, having observed it in her role as a member of the strategic council. She has made hospital management her career for the past 15 years. Aged 42, Claire Charmet has been managing the…
Read MoreBio Asia-Taiwan
BIO Asia–Taiwan 2025 will be held from 16 to 19 July 2026 in Tapei, Taiwan The event brings together bioindustry executives and investors from North America, Europe and Asia to explore business opportunities and to engage with Taiwan’s emerging biotech sector. The five-day gathering includes a three-day conference featuring internationally-renowned speakers, company presentations from…
Read More11 Swiss Life Sciences projects selected by MassChallenge
MassChallenge Switzerland, part of the global MassChallenge network, announced the 103 early-stage startups selected for the 2025 accelerator programme. 11 Swiss Life Sciences projects are in the list. Healthtech Actival (Switzerland): Actival has a patented approach of directly manufacturing clear dental aligners with integrated microfluidic channels. These microfluidic channels act as reservoirs that slowly release beneficial antibacterial…
Read MoreSwiss Health Valley Startups Shine at Major Pitching Events
The Swiss Health Valley continues to be a powerhouse of innovation, as multiple startups made their mark at major pitching events across Europe. These groundbreaking companies are not only transforming health and wellness but also bringing international recognition to the region. At Start Contest 2024-2025, PMAX Labs emerged as the grand prize winner…
Read MoreInnobooster Gebert Rüf Stiftung
Apply before 1 May 2026 for the Gebert Rüf Stiftung Innobooster and get up to a CHF 150,000 support Gebert Rüf Stiftungsupports university-based, high-potential businesses from the Venture Kick program with the aim of substantially accelerating their market entry. The funding line is calling for top talents with convincing proposals of how a research &…
Read MoreSyrhatech Completes A CHF 4.5 Million Financing Round
Syrhatech, a French-Swiss CDMO innovating in the development and manufacture of injectable medical devices based in particular on hyaluronic acid, announces the closing of an investment of CHF 4.5 million, completed with strategic investors. Funding for innovation and industrial capacity This investment will enable Syrhatech to strengthen its R&D team at its site in Geneva, and to deploy a…
Read MorePANORAMAI
Panoramai is taking place from 3 to 5 June 2025 at Campus Unlimitrust in Renens Within the Gen AI ecosystem, discover real-life use cases and AI-powered digital transformation stories with entrepreneurs and business experts. The event also aims to enrich the horizons and potential applications of AI by exploring creative perspectives on uses and…
Read MoreInnofood & Co
InnoFood & Co returns for its 5th edition at the Forum Fribourg on 7 May 2026 A must-attend event dedicated to agri-food innovation in Switzerland, Innofood & Co brings together key players in the ecosystem every year: researchers, entrepreneurs, institutions, producers, and project leaders. This day is designed to bring innovative ideas to the fore…
Read MoreNewBiologix Licences Xcell-Eng-HEK293 Cell Line to Recipharm
NewBiologix, a Biopôle-based (Vaud)Swiss biotech innovator, has granted a non-exclusive licence to Recipharm Advanced Bio. The agreement gives Recipharm access to NewBiologix’s Xcell-Eng-HEK293 cell lines, enabling the efficient production of recombinant Adeno-Associated Viruses (rAAVs) for cell and gene therapies. The licensed cell lines offer high-yield, GMP-ready viral production, accelerating the path to clinical trials.…
Read More